Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

January 26, 2021

FDA approves Boston Scientific’s Parkinson’s brain stimulation system

Photo | Grant Welker Boston Scientific headquarters in Marlborough

Marlborough medical device company Boston Scientific’s fourth generation Vercise Genus Deep Brain Stimulation System has received FDA approval, the company announced on Friday.

The portfolio, which is approved for conditional use in MRI environments, includes a family of Bluetooth-enabled, rechargeable and non-rechargeable, implantable pulse generators powering Cartesia Directional Leads, which are intended to provide symptom relief for Parkinson’s disease.

The Vercise Genus System treats Parkinson’s symptoms by delivering targeted electrical stimulation through the surgically-implanted leads in the brain, according to Boston Scientific. 

FDA approval gives the greenlight to the system’s fourth generation, which originally launched in 2012. The system launched in Europe in September.

Sign up for Enews

WBJ Web Partners

Related Content

0 Comments

Order a PDF